ALN-AT3SC-003 Hemophilia A or B

Bleeding and Clotting Disorders

Protocol:ALN-AT3SC-003

Condition or Disease: Hemophilia A or B

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX

Principal I investigator: Joseph Lasky III, MD

More Info: //clinicaltrials.gov/ct2/show/NCT03417102

Share This Post

Explore More News

Blog

Rare Disease Advisory Council seeks input for healthier Nevada

The Rare Disease Advisory Council is seeking input from the public to help improve the health of Nevada residents. The council is focused on addressing the needs of those with rare diseases and is looking for feedback from patients, caregivers, and healthcare providers. The goal is to gather information that can be used to develop strategies and policies to improve the lives of those affected by rare diseases in Nevada.

Blog

Cure 4 The Kids Foundation Announces Senior Leadership Changes

Cure 4 The Kids Foundation is pleased to announce the appointment of Christine Tonn as its new chief executive officer (CEO), effective January 1, 2024. This promotion is part of a board of directors-supported management succession plan.